QURE

QURE

USD

uniQure N.V. Ordinary Shares

$30.440-0.370 (-1.201%)

リアルタイム価格

Healthcare
バイオテクノロジー
オランダ

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$30.810

高値

$32.490

安値

$28.500

出来高

8.90M

企業ファンダメンタルズ

時価総額

1.9B

業種

バイオテクノロジー

Netherlands

取引統計

平均出来高

3.75M

取引所

NMS

通貨

USD

52週レンジ

安値 $5.35現在値 $30.440高値 $71.5

関連ニュース

GlobeNewswire

uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (QURE)

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. ("uniQure" or the "Company") (NASDAQ:QURE). The investigation concerns whether the

もっと見る
Analyst Upgrades

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

もっと見る
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Analyst Upgrades

Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38

Goldman Sachs analyst Salveen Richter maintains uniQure with a Neutral and lowers the price target from $56 to $38.

もっと見る
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38
Analyst Upgrades

RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45

RBC Capital analyst Luca Issi maintains uniQure with a Outperform and lowers the price target from $65 to $45.

もっと見る
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45
Analyst Upgrades

William Blair Downgrades uniQure to Market Perform

William Blair analyst Sami Corwin downgrades uniQure from Outperform to Market Perform.

もっと見る
William Blair Downgrades uniQure to Market Perform
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on uniQure, Lowers Price Target to $70

HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure with a Buy and lowers the price target from $110 to $70.

Analyst Upgrades

Chardan Capital Maintains Buy on uniQure, Lowers Price Target to $53

Chardan Capital analyst Daniil Gataulin maintains uniQure with a Buy and lowers the price target from $76 to $53.